Acurx’s ibezapolstat shows efficacy in published Phase 2b trial results

Acurx (ACXP) Pharmaceuticals’ lead antibiotic candidate, ibezapolstat, is ready to advance to international Phase 3 clinical trials for treatment of patients with C. difficile infection, or CDI. The company announced the publication of results in Lancet Microbe of its Phase 2b clinical study. The Phase 2b study was initiated to assess the efficacy, safety, and associated microbiome changes of IBZ versus standard of care vancomycin. In the publication, Professor Garey summarized results which included high rates of CC in IBZ-treated subjects treated with no recurrence; furthermore, IBZ was found to be safe, well-tolerated, and associated with the preservation and restoration of key health-promoting bacteria responsible for bile acid homeostasis, a key component in preventing recurrent CDI. The publication establishes that IBZ shows potential as a novel antibiotic treatment for CDI with high rates of CC and SCC while minimally disturbing the protective gut microbiota, thus further supporting its clinical development.